
#263 – John Abramson: Big Pharma
Lex Fridman Podcast
00:00
Pharmaceutical Influence and Public Health
This chapter explores the controversial dynamics between pharmaceutical companies and regulatory agencies, focusing on the 'revolving door' phenomenon and conflicts of interest. It particularly critiques the FDA's approval of the Alzheimer's drug Adjahelm, raising concerns about the impact of financial ties on regulatory decisions. The discussion advocates for stricter regulations, emphasizing the need for a shift in funding from drug research to preventive health measures to improve public health outcomes.
Transcript
Play full episode